Transplantation strategies in AML: AMLCG data.
Allogeneic stem cell transplantation (allo-SCT) is considered the most potent postremission therapy for acute myeloid leukemia (AML). Its superior antileukemic activity is largely ascribed to the powerful graft-versus-leukemia (GvL) effects exerted by donor lymphocytes. However, due to considerable treatment-related lethality the gains in relapse prevention do not necessarily translate into survival advantages in the overall patient population. Therefore, allo-SCT for adult patients with AML in first complete remission (CR1) is currently recommended only for younger and medically fit patients who are at intermediate to high risk of relapse and have an HLA-identical sibling donor. Stem cell allografting from alternative donors in CR1 is considered an option for high risk patients as defined by cytogenetic abnormalities or incomplete response after one course of induction chemotherapy and should usually be performed in the context of a clinical protocol.
Kienast
J
J
Dept. of Medicine / Hematology and Oncology, University of Muenster, Muenster, Germany.
Stelljes
M
M
Berning
B
B
Kröger
M
M
Sauerland
M C
MC
Heinecke
A
A
Schoch
C
C
Wörmann
B
B
Büchner
T
T
Hiddemann
W
W
Berdel
W E
WE
D000208:Acute Disease; D016026:Bone Marrow Transplantation; D018572:Disease-Free Survival; D005858:Germany; D006801:Humans; D007951:Leukemia, Myeloid / Q000401:mortality / Q000601:surgery*; D033581:Stem Cell Transplantation; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous